When do the JADELLE patents expire, and when will JADELLE go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Population Council	JADELLE	levonorgestrel	IMPLANT;IMPLANTATION	020544-001	Nov 1, 1996		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 1, 2026

JADELLE (levonorgestrel) is a legacy US oral contraceptive product with a patent and exclusivity profile that is typically dominated by older composition, formulation, and dosing regimen filings. For investment purposes, the key variable is not near-term regulatory uncertainty but the timing and certainty of generic market entry driven by Orange Book status, patent litigation or settlements (if any), and formulation-specific switching risk.

What patents protect JADELLE (levonorgestrel) in the US?

JADELLE is generally treated as a brand oral contraceptive using levonorgestrel in combination with an estrogen component depending on the marketed strength and regimen. Patent coverage for oral contraceptives typically clusters into four groups: (1) composition of the active ingredient(s), (2) specific ratios or dosing regimens, (3) solid oral dosage formulations and manufacturing processes, and (4) method-of-use claims tied to contraception efficacy.

Featured answer (investment-relevant): For legacy oral contraceptives, patent estates tend to be older and concentrated in formulation and regimen patents rather than broad “active ingredient” patents. Generic entry risk usually becomes a binary event once Orange Book-listed patents relevant to the approved NDA are cleared through expiration, non-infringement, or settlement.

How many patents cover JADELLE Orange Book listings?

Investment due diligence for JADELLE should focus on Orange Book “List of Patent(s)” tied to the approved NDA/ANDA application(s). The count that matters is the number of Orange Book patents with the following attributes:

Patent type indicating composition, formulation, or method-of-use (not only manufacturing)
Remaining life at the forecast horizon
Whether any are subject to a Paragraph IV certification history or litigation

Actionable investment checkpoint: Build a patent risk heat map by:

Patent number
Remaining expiration date
Claim scope (composition vs regimen vs method)
Whether the patent is likely to block AB-rated generic switching or only delay substitution.

Which assignees and inventors typically hold oral contraceptive patents?

Oral contraceptive patent estates often sit with the original NDA holder and/or assignees created through corporate transactions. For investment analysis, your diligence should map:

Current Orange Book assignee (as listed)
Chain of title for major patents
Whether key patents are held by an operating company or a transfer entity.

What formulations are protected for JADELLE?

In contraceptives, formulation protection usually targets:

Tablet composition (binders, disintegrants, coating systems)
Bioavailability-related formulation attributes (dissolution, particle size, polymorph or excipient interactions)
Stability and packaging (if claimed)

Switching relevance: Investors should treat formulation patents as high sensitivity for “label-identical” generics. If generic labels differ in tablet appearance, dosing schedule presentation, or inert ingredient sets, litigation or design-around can occur.

When does JADELLE lose exclusivity in the US?

Exclusivity for brand oral contraceptives can arise from:

New chemical entity (NCE) or new molecular entity (NME) exclusivity (unlikely for legacy levonorgestrel products)
3-year exclusivity based on supplemental approvals with new clinical investigations
Patent exclusivity under the Hatch-Waxman framework (patent term plus any applicable regulatory exclusivity)

Featured answer (timing): For JADELLE-style legacy contraceptives, the effective exclusivity driver in practice is patent expiration and any triggered Paragraph IV litigation, not FDA exclusivity tied to a specific “new” clinical supplement.

Patent expiration vs FDA exclusivity: what matters for investment?

From a market-entry perspective:

Patent expiration clears the generic “blocking” patents
FDA exclusivity can delay approval of certain applications even if patents expire, but in legacy contraceptives it is often not the dominant limiter
Settlement agreements can extend practical brand protection beyond the last patent date

When do generics launch once patents expire?

Investment modeling should incorporate a “time-to-market” window after last blocking patent expiry:

Litigation wrap-up and settlement implementation schedules
Manufacturing scale-up and QC release
Distribution contracting and payer formulary switches
Any “authorized generic” dynamics if settlement permits

Scenario framing: Treat generic entry probability as a function of:

Last blocking Orange Book patent expiration date
Whether Paragraph IV challenges have already been filed and resolved
Whether settlement restricts launch dates or uses phased-entry terms.

What generic entry risks exist for JADELLE?

Generic entry risks are dominated by Hatch-Waxman mechanics:

Paragraph IV challenges to Orange Book patents
Potential non-infringement or invalidity positions
Settlement terms that may include delayed entry, licensing, or damages

Featured answer (risk): The highest generic launch risk is when Orange Book-listed patents have expired or are no longer enforced due to stipulation, final judgment, or settlement.

What Paragraph IV challenges affect JADELLE?

Your diligence should scan:

FDA Patent Certification history (Paragraph I, II, III, IV)
Court filings tied to the NDA
Whether additional patents were later listed in the Orange Book, extending the “blocking” list

Investment due diligence rule: If there is any post-approval “late listing” of patents under 30 months or “automatic” addition provisions, it can reset the risk profile for generic applicants.

How does JADELLE compete with other levonorgestrel oral contraceptives?

Market switching is not only about legal entry. It is about:

Therapeutic equivalence and AB-rating
Price erosion and rebate structures
Payer preference by formulary tier
Formulation or dosing regimen presentation (especially for patient adherence)

Competitor angle: Investors should map the “closest substitutes” in the same therapeutic class:

Other levonorgestrel-containing combined oral contraceptives
Alternative progestins with similar dosing schedules
Overlap with generics already in the market

How strong is the patent estate for JADELLE?

Patent strength for legacy oral contraceptives is evaluated by:

Remaining term of each Orange Book patent
Breadth of claims (composition breadth usually weaker post-expiration than specific regimen/formulation claims)
Litigation history quality (asserted vs sustained positions)
Likelihood of design-around (especially for formulation and manufacturing claims)

What patent strength indicators should investors use?

Use a scoring approach per listed patent:

Claim breadth score (composition/regimen/formulation)
Remaining term score (months until expiration)
Enforceability score (procedural posture, venue, history)
Design-around score (is the claim tied to specific excipients/process steps)
Market relevance score (blocks approval vs only affects labeling differentiation)

Featured answer (investment-ready): A “thin but last-mile” estate often drives settlement behavior. If only one or two formulation/regimen patents remain, generic applicants usually either settle quickly or litigate on narrow claim scope.

What patent litigation affects JADELLE, including settlements and consent decrees?

Patent litigation impact is typically binary for legacy products:

No active litigation with remaining blocking patents: generic entry accelerates on expiration
Active litigation or unresolved appeal: launch timing shifts to outcome-driven scenarios
Settlement agreements: entry is governed by contractual launch dates and sometimes authorized generic restrictions

What to check in court dockets for JADELLE

Investment-grade review should capture:

Case caption and parties (brand NDA holder vs ANDA filer)
Asserted patents and claim charts summary
Procedural timeline (TRO/PI motions, claim construction dates, final judgment dates)
Appeal status and any stay orders

How do settlements usually price brand protection for legacy OCs?

Settlements in oral contraceptives commonly include:

Date-certain delayed launch for generic
License terms for generic to enter with AB-rated label
Authorized generic handling (brand-supplied supply or exclusivity carve-outs)
Payment/compensation terms when permitted under applicable law

Investor focus: Model brand revenue sensitivity to the settlement entry date, not merely patent expiration.

What is the Orange Book status of JADELLE (NDA/ANDA), and which patents block FDA approval?

Orange Book status determines:

Which patents are listed as blocking
Whether an ANDA has been approved and is commercially marketed
Whether there are pending applications certified under Paragraph IV

Featured answer (regulatory/commercial): The relevant “blocking set” is the subset of Orange Book patents that are:

Still in force
Asserted as the basis for infringement in any litigation
Certified against by would-be generics

How Orange Book listings translate into generic launch barriers

For each Orange Book patent:

If expired: it drops out as a barrier
If there is a Paragraph IV litigation stay: launch timing follows resolution
If a patent is found invalid/non-infringed: it clears the specific application’s approval path

What FDA status and approval pathway governs JADELLE?

For a legacy oral contraceptive:

Brand remains under an NDA
Generics enter through ANDA referencing the brand
Any formulation changes could trigger supplemental approvals (and potentially 3-year exclusivity if new clinical studies exist, though that is typically rare for long-settled OCs)

Featured answer (regulatory): FDA pathway risk is usually low for JADELLE compared with products with complex manufacturing changes. The primary risk is legal/regulatory interplay via Orange Book.

What labeling and substitution dynamics affect sales after generic entry?

Generic entry impacts:

Patient switch behavior (pharmacy dispensing defaults and physician inertia)
Rebate and contracting pressure
Any treatment interruptions if pill colors or schedules appear different

Commercial implication: Even AB-rated generics can see slower ramp if payer contracts are brand-favorable or if patient adherence is impacted.

How does JADELLE compare with other levonorgestrel oral contraceptives on market and IP exposure?

Investment positioning requires comparing:

Net price and discount levels
Share stability after generic entry in the same therapeutic cluster
Patent estate residual term across competitors
Whether competitors are already genericized (reducing incremental pricing power for JADELLE)

What is the revenue exposure profile for JADELLE-style legacies?

Typically:

Higher revenue sensitivity to generic entry timing than to FDA inspection outcomes
Rapid margin compression after AB-rated generics enter
Brand-specific retention only where formulation differences or supply constraints exist

Key Takeaways

JADELLE’s investment risk is primarily tied to Orange Book patent status and any resolved or pending Hatch-Waxman challenges, not ongoing FDA innovation risk.
Generic entry is likely a schedule-and-legal event: model launch probability from the last blocking Orange Book patent expiration date and any settlement-driven entry date.
Patent strength for legacy levonorgestrel oral contraceptives is often narrow at the end game, typically concentrated in formulation or regimen patents that can still drive settlement behavior.
Commercial impact usually becomes acute after AB-rated generics enter, with rapid rebate-driven price compression and distribution switching.

FAQs

How do Orange Book “List of Patents” entries determine when JADELLE generics can launch?
What is the most common patent type blocking generic oral contraceptives like JADELLE at the end of patent life?
How do settlement agreements typically change generic launch timing for legacy contraceptive brands?
What labeling or formulation differences can slow real-world switching even when generics are AB-rated for JADELLE?
Does exclusivity (3-year or other FDA exclusivity) usually extend protection for legacy levonorgestrel contraceptives beyond patent expiry?

References

FDA. “Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).” U.S. Food and Drug Administration.
U.S. Patent and Trademark Office (USPTO). “Patent Terms and Expiration.” USPTO.
FDA. “Hatch-Waxman: Approved Drug Products and ANDAs.” U.S. Food and Drug Administration.

JADELLE Drug Patent Profile

When do Jadelle patents expire, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jadelle

AI Deep Research

Questions you can ask:

Summary for JADELLE

US Patents and Regulatory Information for JADELLE

JADELLE (levonorgestrel) patent, exclusivity, and investment fundamentals analysis for US generic and settlement risk